Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Investment analysts at Zacks Investment Research issued their Q1 2018 earnings per share estimates for shares of Tonix Pharmaceuticals in a research note issued to investors on Monday. Zacks Investment Research analyst D. Bautz anticipates that the company will earn ($0.68) per share for the quarter. Zacks Investment Research also issued estimates for Tonix Pharmaceuticals’ Q2 2018 earnings at ($0.71) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.78) EPS, FY2018 earnings at ($2.87) EPS, FY2019 earnings at ($2.15) EPS and FY2020 earnings at ($2.03) EPS.
TNXP has been the topic of a number of other research reports. ValuEngine upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Aegis reiterated a “buy” rating on shares of Tonix Pharmaceuticals in a report on Friday, December 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $8.33.
Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Monday, March 12th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10.
An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Vanguard Group Inc. increased its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 184,377 shares of the company’s stock after acquiring an additional 41,264 shares during the quarter. Vanguard Group Inc. owned about 2.46% of Tonix Pharmaceuticals worth $799,000 at the end of the most recent quarter. 15.21% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3294447/analysts-issue-forecasts-for-tonix-pharmaceuticals-holding-corp-s-q1-2018-earnings-tnxp.html.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company?s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.